Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight.
NICE has defended a trio of decisions on new therapies for multiple myeloma, which saw two drugs approved for restricted use in England and Wales and a third turned down altogether.
Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its bloc
Johnson & Johnson and partner Legend Biotech are celebrating a big win in their efforts to expand the use of CAR-T therapy Carvykti for multiple myeloma, after showing a survival benefi
Sanofi has hit back on a decision by NICE not to recommend NHS use of Sarclisa as part of a regimen for relapsed and refractory multiple myeloma (RRMM), claiming the agency would not consid
Health plans, employers, and healthcare providers remain committed to adopting digital solutions and expect to increase their spending on the category, according to a recent poll.
